RHO and osteosarcoma: New signatures of four pseudogenes, RP11-326A19.5, RP4-706A16.3, RPL7AP28, and RPL11-551L14.1, for osteosarcoma were found, which is a promising independent survival predictor and serves as an important biomarker for clinical treatment of osteosarcoma to improve patient management [78].